Black Diamond: Mapping allostery
Black Diamond debuts with plans to identify, target allosteric mutant oncogenes
Black Diamond Therapeutics Inc. emerged from stealth on Tuesday with a platform to mine and drug baskets of allosteric mutant oncogenes using troves of human sequencing data that contain non-catalytic mutations previously deemed non-actionable. The company debuted with $20 million in a tranched series A round from Versant Ventures and represents the first start-up to launch from Versant’s Ridgeline incubator in Basel.
Allosteric mutations occur